Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com


PeptiDream and Takeda Expand its Research and License Agreement to

Shots: As per expanded collaboration, PeptiDream to receive ~$3.5B as up front, preclinical, development, launch, and commercial milestones and is eligible to receive royalties on sales of any product that emerges from the collaboration The extended collaboration expands the use of the TfR1 binding peptide ligands for CNS targets associated with neurodegeneration & allow Takeda […]Read More


Amgen to Acquire Teneobio for ~$2.5B

Shots: Amgen to acquire all outstanding shares of Teneobio for $900M as up front and $1.6B in cash as contingent milestones to Teneobio equity holders. The transaction is expected to be closed in H2’21 The acquisition will boost Amgen’s abilities to develop innovative therapies and expand its portfolio with the addition of early-stage oncology assets […]Read More


AstraZeneca and Regeneron Collaborate to Research, Develop and Commercialize Therapies

Shots: The companies collaborated to research, develop & commercialize small molecules directed against the GPR75 target with the potential to treat obesity and related co-morbidities The collaboration builds on the findings from the Regeneron Genetics Center of rare genetic mutations in the GPR75 gene associated with protection against obesity and on early joint research initiated […]Read More


GSK’s Shingrix Receives the US FDA’s Approval to Prevent Shingles

Shots: The approval is based on studies evaluating the safety & efficacy of Shingrix in adults aged ≥18yrs. who had undergone auHSCT and those undergoing treatment for hematological malignancies (post-hoc analysis) The safety & immunogenicity data were generated in adults who were or anticipated to be, immunodeficient/immunosuppressed due to known therapy including patients with HIV, […]Read More

Clinical Trials

Prothena Presents Preclinical Data of its Alzheimer’s Candidates at AAIC

Shots: Prothena presents new data for PRX012 (anti-amyloid beta (Aβ) Ab) and the company’s dual Aβ-tau vaccine program being developed for the prevention and treatment of AD The preclinical data of PRX012 (SC) highlights significant ex vivo clearance of both pyroglutamate-modified and -unmodified Aβ plaque from AD brain at concentrations expected to be reached in […]Read More